

BEGIN 5,6,55,154,155,156,312,399,BIOTECH,BIOSCI
>>> 135 is unauthorized

Set Items Description

?

S (VACCINE OR IMMUNOTHERAP?) AND (NEU OR MET OR RAS) (5N) (CYTOKINE? OR IL OR IL-2 O
Processed 20 of 37 files ...

Processing

Completed processing all files

668894	VACCINE
345777	IMMUNOTHERAP?
53574	NEU
456667	MET
285208	RAS
1292311	CYTOKINE?
1414506	IL
9162	IL-2
8235	IL-4
14566	GM-CSF
3639	((NEU OR MET) OR RAS) (5N) (((CYTOKINE? OR IL) OR IL-2) OR IL-4) OR GM-CSF)
S1 185	(VACCINE OR IMMUNOTHERAP?) AND (NEU OR MET OR RAS) (5N) (CYTOKINE? OR IL OR IL-2 OR IL-4 OR GM-CSF)

?

RD S1

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.

...examined 50 records (50)

...examined 50 records (100)

...examined 50 records (150)

...completed examining records

S2 76 RD S1 (unique items)

?

S S2 NOT PY>2002

>>>One or more prefixes are unsupported

>>> or undefined in one or more files.

76 S2

17518309 PY>2002

S3 44 S2 NOT PY>2002

?

Display 3/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0013386397 BIOSIS NO.: 200100558236

**Combined allogeneic tumor cell vaccination and systemic interleukin 12
prevents mammary carcinogenesis in HER-2/neu transgenic mice**

AUTHOR: Nanni Patrizia; Nicoletti Giordano; De Giovanni Carla; Landuzzi
Lorena; Di Carlo Emma; Cavallo Federica; Pupa Serenella M; Rossi Ilaria;
Colombo Mario P; Ricci Cinzia; Astolfi Annalisa; Musiani Piero; Forni
Guido; Lollini Pier-Luigi (Reprint)

AUTHOR ADDRESS: Sezione di Cancerologia, Viale Filopanti 22, I-40126,
Bologna, Italy**Italy

JOURNAL: Journal of Experimental Medicine 194 (9): p1195-1205 November 5,
2001

MEDIUM: print

ISSN: 0022-1007

DOCUMENT TYPE: Article
RECORD TYPE: Abstract

-more-

?

Display 3/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.
LANGUAGE: English

- end of record -

?

Display 3/3/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0013247175 BIOSIS NO.: 200100419014

**A recombinant IgG3-(IL-2) fusion protein for the treatment of human
HER2/neu expressing tumors**

AUTHOR: Penichet Manuel L; Dela Cruz Jay S; Shin Seung-Uon; Morrison Sherie
L (Reprint)

AUTHOR ADDRESS: Department of Microbiology and Molecular Genetics,
University of California, Los Angeles, 405 Hilgard Avenue, Los Angeles,
CA, 90095-1489, USA**USA

JOURNAL: Human Antibodies 10 (1): p43-49 2001 2001

MEDIUM: print

ISSN: 1093-2607

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

- end of record -

?

Display 3/3/3 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0012526667 BIOSIS NO.: 200000244980

**In vivo anti-tumor activity of an anti-HER-2/neu-IL-12 antibody fusion
protein**

AUTHOR: Peng Lisan S (Reprint); Penichet Manuel L (Reprint); Morrison
Sherie L (Reprint)

AUTHOR ADDRESS: UCLA, Los Angeles, CA, USA**USA

JOURNAL: Proceedings of the American Association for Cancer Research Annual
Meeting (41): p287 March, 2000 2000

MEDIUM: print

CONFERENCE/MEETING: 91st Annual Meeting of the American Association for
Cancer Research. San Francisco, California, USA April 01-05, 2000;
20000401

ISSN: 0197-016X

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Citation

-more-

?

Display 3/3/3 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.
LANGUAGE: English

- end of record -

?

Display 3/3/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0011654819 BIOSIS NO.: 199800449066

Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele

AUTHOR: Bergmann-Leitner Elke S; Kantor Judith A; Shupert W Lesley; Schlom Jeffrey (Reprint); Abrams Scott I

AUTHOR ADDRESS: Lab. Tumor Immunol. and Biol., Natl. Cancer Inst., Natl. Health, Build. 10, Room 8B07, 10 Center Drive, Bethesda, MD 20892-1750, USA**USA

JOURNAL: Cellular Immunology 187 (2): p103-116 Aug. 1, 1998 1998

MEDIUM: print

ISSN: 0008-8749

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

- end of record -

?

Display 3/3/5 (Item 5 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0010263258 BIOSIS NO.: 199698731091

Development and characterization of an interleukin-2 transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules

AUTHOR: Santin Alessandro D; Ioli Gene R; Hiserodt John C; Manetta Alberto; Percorelli Sergio; Disaia Phillip J; Granger Gale A (Reprint)

AUTHOR ADDRESS: Dep. Mol. Biol. Biochem., Univ. California Irvine, Irvine, CA 92717-3900, USA**USA

JOURNAL: American Journal of Obstetrics and Gynecology 174 (2): p633-640 1996 1996

ISSN: 0002-9378

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

- end of record -

?

Display 3/3/6 (Item 6 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0010003351 BIOSIS NO.: 199598471184

Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2

AUTHOR: Gooding R (Reprint); Riches P; Dadian G; Moore J; Gore M

AUTHOR ADDRESS: Dep. Haematol., Royal Postgrad. Med. Sch., Hammersmith

Hosp., Du Cane Road, London W12 0NN, UK**UK
JOURNAL: British Journal of Cancer 72 (2): p452-455 1995 1995
ISSN: 0007-0920
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

- end of record -

?

Display 3/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0009987912 BIOSIS NO.: 199598455745
Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study
AUTHOR: Goedegebuure Peter S; Douville Linda M; Li Hong; Richmond Glenn C; Schoof Deric D; Scavone Marybeth; Eberlein Timothy J (Reprint)
AUTHOR ADDRESS: Div. Surgical Oncol., Dep. Surgery, Brigham and Women's Hosp., 75 Francis St., Boston, MA 02115, USA**USA
JOURNAL: Journal of Clinical Oncology 13 (8): p1939-1949 1995 1995
ISSN: 0732-183X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

- end of record -

?

Display 3/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0008396590 BIOSIS NO.: 199294098431
REDUCED TUMORIGENICITY OF FIBROSARCOMAS WHICH CONSTITUTIVELY GENERATE IL-1-ALPHA EITHER SPONTANEOUSLY OR FOLLOWING IL-1-ALPHA GENE TRANSFER
AUTHOR: DOUVDEVAN A (Reprint); HULEIHEL M; ZOELLER M; SEGAL S; APTE R N
AUTHOR ADDRESS: DEP MICROBIOL IMMUNOL, FAC HEALTH SCI, BEN-GERION UNIV NEGREV, BEER-SHEVA 94105, ISRAEL**ISRAEL
JOURNAL: International Journal of Cancer 51 (5): p822-830 1992
ISSN: 0020-7136
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

- end of record -

?

Display 3/3/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0007280534 BIOSIS NO.: 199090065013
LEVAMISOLE MEETS SULFHYDRYL REQUIREMENTS OF CTLL-2 CELLS AND MEDIATES ENHANCED PROLIFERATIVE RESPONSE TO MITOGEN STIMULATION WITHOUT INCREASING INTERLEUKIN-2 PRODUCTION
AUTHOR: OBIRI N I (Reprint); DUPERE S L; PRUETT S B; LACKEY A; EMMA D; O'CONNOR T E

AUTHOR ADDRESS: 1302 GRANVILLE RD, FRANKLIN, TENN 37064, USA**USA
JOURNAL: Journal of Biological Response Modifiers 9 (3): p288-299 1990
ISSN: 0732-6580
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

- end of record -

?

S (VACCINE OR IMMUNOTHERAP?) AND (NEU OR MET OR RAS) (5N) (CYTOKINE? OR IL OR IL-2 O
668894 VACCINE
345777 IMMUNOTHERAP?
53574 NEU
456667 MET
285208 RAS
1292311 CYTOKINE?
1414506 IL
9162 IL-2
8235 IL-4
14566 GM-CSF
0 VECTOR\$
0 ((NEU OR MET) OR RAS) (5N) (((CYTOKINE? OR IL) OR IL-2) OR
IL-4) OR GM-CSF) (10N) VECTOR\$
S4 0 (VACCINE OR IMMUNOTHERAP?) AND (NEU OR MET OR RAS) (5N)
(CYTOKINE? OR IL OR IL-2 OR IL-4 OR GM-CSF) (10N) VECTOR\$

?

S (VACCINE OR IMMUNOTHERAP?) AND (NEU OR MET OR RAS) (5N) (CYTOKINE? OR IL OR IL-2 O
668894 VACCINE
345777 IMMUNOTHERAP?
53574 NEU
456667 MET
285208 RAS
1292311 CYTOKINE?
1414506 IL
9162 IL-2
8235 IL-4
14566 GM-CSF
2090978 VECTOR?
77 ((NEU OR MET) OR RAS) (5N) (((CYTOKINE? OR IL) OR IL-2) OR
IL-4) OR GM-CSF) (10N) VECTOR?
S5 21 (VACCINE OR IMMUNOTHERAP?) AND (NEU OR MET OR RAS) (5N)
(CYTOKINE? OR IL OR IL-2 OR IL-4 OR GM-CSF) (10N) VECTOR?

?

RD S5

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.

...completed examining records

S6 8 RD S5 (unique items)

?

Display 6/3/1 (Item 1 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0010263258 BIOSIS NO.: 199698731091

Development and characterization of an interleukin-2 transduced human

ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules

AUTHOR: Santin Alessandro D; Ioli Gene R; Hiserodt John C; Manetta Alberto; Percorelli Sergio; Disaia Phillip J; Granger Gale A (Reprint)

AUTHOR ADDRESS: Dep. Mol. Biol. Biochem., Univ. California Irvine, Irvine, CA 92717-3900, USA**USA

JOURNAL: American Journal of Obstetrics and Gynecology 174 (2): p633-640 1996 1996

ISSN: 0002-9378

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

- end of record -

?

Display 6/3/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0008396590 BIOSIS NO.: 199294098431

REDUCED TUMORIGENICITY OF FIBROSARCOMAS WHICH CONSTITUTIVELY GENERATE IL-1-ALPHA EITHER SPONTANEOUSLY OR FOLLOWING IL-1-ALPHA GENE TRANSFER

AUTHOR: DOUVDEVAN A (Reprint); HULEIHEL M; ZOELLER M; SEGAL S; APTE R N

AUTHOR ADDRESS: DEP MICROBIOL IMMUNOL, FAC HEALTH SCI, BEN-GERION UNIV

NEGREV, BEER-SHEVA 94105, ISRAEL**ISRAEL

JOURNAL: International Journal of Cancer 51 (5): p822-830 1992

ISSN: 0020-7136

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

- end of record -

?

Display 6/3/3 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

141105249 CA: 141(7)105249w PATENT

Recombinant viral vectors expressing IL-15 and antigen epitope for vaccines against viral or bacterial infection and cancer

INVENTOR(AUTHOR): Perera, Liyange P.; Waldmann, Thomas A.; Oh, Sang-kon; Berzofsky, Jay A.

LOCATION: USA

ASSIGNEE: The Government of the United States of America, as Represented by the Secretary Department of Health and Human Services

PATENT: PCT International ; WO 200458278 A1 DATE: 20040715

APPLICATION: WO 2003US39967 (20031215) *US PV433703 (20021216)

PAGES: 81 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-035/00A; A61K-048/00B; C12N-015/63B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ;

-more-

?

Display 6/3/3 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.
OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT;
TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM
; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU;
TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT;
LU; MC; NL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR; NE; SN; TD; TG

- end of record -

?

Display 6/3/4 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

128320551 CA: 128(26)320551a PATENT

Vaccines and vector vaccines using lymphokines and cytokines or the genes encoding them

INVENTOR(AUTHOR): Kim, Jong J.; Bagarazzi, Mark L.; Wang, Bin; Boyer, Jean D.; Weiner, David B.

LOCATION: USA

ASSIGNEE: Trustees of the University of Pennsylvania; Apollon, Inc.; Kim, Jong J.; Bagarazzi, Mark L.; Wang, Bin; Boyer, Jean D.; Weiner, David B.

PATENT: PCT International ; WO 9817799 A1 DATE: 19980430

APPLICATION: WO 97US19502 (19971023) *US 28613 (19961023)

PAGES: 137 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/18A;
A61K-048/00B; A61K-031/00B DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA;
BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; HU; ID;
IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN;
MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA;

-more-

?

Display 6/3/4 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

UG; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

DESIGNATED REGIONAL: GH; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; DE; DK;
ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA;
GN; ML; MR; NE; SN; TD; TG

- end of record -

?

Display 6/3/5 (Item 1 from file: 24)

DIALOG(R)File 24:CSA Life Sciences Abstracts

(c) 2005 CSA. All rts. reserv.

0001985866 IP ACCESSION NO: 4558261

A Single-Chain IL-12 IgG3 Antibody Fusion Protein Retains Antibody Specificity and IL-12 Bioactivity and Demonstrates Antitumor Activity

Peng, LS; Penichet, ML; Morrison, SL*

Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, 405 Hilgard Avenue, Los Angeles, CA 90095-1489, USA, [mailto:shერიem@microbio.lifesci.ucla.edu]

Journal of Immunology, v 163, n 1, p 250-258, July 1, 1999

PUBLICATION DATE: 1999

DOCUMENT TYPE: Journal Article
RECORD TYPE: Abstract
LANGUAGE: English

-more-

?

Display 6/3/5 (Item 1 from file: 24)
DIALOG(R)File 24:CSA Life Sciences Abstracts
(c) 2005 CSA. All rts. reserv.
SUMMARY LANGUAGE: English
ISSN: 0022-1767
FILE SEGMENT: Immunology Abstracts; Medical & Pharmaceutical Biotechnology Abstracts

- end of record -

?

Display 6/3/6 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0360818 DBR Accession No.: 2005-06522 PATENT
New DNA vaccine containing tumor-associated gene and cytokine gene, useful for enhancing the immune response of the host through the co-expression of tumor-associated antigen and cytokine, thus inhibiting or retarding tumor growth - virus vector, plasmid or liposome-mediated oncogene, interleukin or granulocyte-macrophage colony stimulating factor gene transfer for use in cancer nucleic acid and gene therapy
AUTHOR: LAI M; LIN C
PATENT ASSIGNEE: UNIV NAT CHENG KUNG 2005
PATENT NUMBER: US 20050020520 PATENT DATE: 20050127 WPI ACCESSION NO.: 2005-100855 (200511)
PRIORITY APPLIC. NO.: TW 202W-121934 APPLIC. DATE: 20020924
NATIONAL APPLIC. NO.: US 663048 APPLIC. DATE: 20030916
LANGUAGE: English

- end of record -

?

Display 6/3/7 (Item 2 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0336808 DBR Accession No.: 2004-09100 PATENT
Novel tumor-associated PAM4 antibody binding a domain located between amino terminus and start of repeat domain of MUC1, derived by immunization and/or selection with mucin, useful for treating pancreatic cancer - involving vector-mediated gene transfer and expression in host cell
AUTHOR: GOLD D V; GOLDENBERG D M; HANSEN H
PATENT ASSIGNEE: IMMUNOMEDICS INC; MCCALL J D 2003
PATENT NUMBER: WO 2003106497 PATENT DATE: 20031224 WPI ACCESSION NO.: 2004-156341 (200415)
PRIORITY APPLIC. NO.: US 388313 APPLIC. DATE: 20020614
NATIONAL APPLIC. NO.: WO 2003GB2585 APPLIC. DATE: 20030616
LANGUAGE: English

- end of record -

?

Display 6/3/8 (Item 3 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0261616 DBR Accession No.: 2001-01024

Induction of antitumor immunity with combination of HER2/neu nucleic acid and interleukin-2 gene-modified tumor vaccine - cytokine-mediated gene therapy of cancer

AUTHOR: Chen S A; Tsai M H; Wu F T; Hsiang A; Chen Y L; Lei H Y; Tzai T S; Leung H W C; Jin Y T; Hsieh C L; Hwang L H; +Lai M D

CORPORATE AFFILIATE: Univ.Cheng-Kung-Nat. Univ.Taiwan-Nat.Inst.Microbiol.

CORPORATE SOURCE: Department of Biochemistry, College of Medicine, National Cheng Kung University, Tainan, Taiwan. email:al211207@mail.ncku.edu.tw

JOURNAL: Clin.Cancer Res. (6, 11, 4381-88) 2000

ISSN: 1078-0432 CODEN: CCREF

LANGUAGE: English

- end of record -

?

Display 6/9/8 (Item 3 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0261616 DBR Accession No.: 2001-01024

Induction of antitumor immunity with combination of HER2/neu nucleic acid and interleukin-2 gene-modified tumor vaccine - cytokine-mediated gene therapy of cancer

AUTHOR: Chen S A; Tsai M H; Wu F T; Hsiang A; Chen Y L; Lei H Y; Tzai T S; Leung H W C; Jin Y T; Hsieh C L; Hwang L H; +Lai M D

CORPORATE AFFILIATE: Univ.Cheng-Kung-Nat. Univ.Taiwan-Nat.Inst.Microbiol.

CORPORATE SOURCE: Department of Biochemistry, College of Medicine, National Cheng Kung University, Tainan, Taiwan. email:al211207@mail.ncku.edu.tw

JOURNAL: Clin.Cancer Res. (6, 11, 4381-88) 2000

ISSN: 1078-0432 CODEN: CCREF

LANGUAGE: English

ABSTRACT: Induction of antitumor immunity with combination of HER2/neu nucleic acid vaccine and interleukin (IL)-2 gene modified tumor vaccine, was studied. The IL-2 and IL-4 retro virus vectors were

-more-

?

Display 6/9/8 (Item 3 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

constructed by replacing granulocyte-macrophage colony stimulating factor gene of a previously constructed retro virus vector with the human IL-2 or mouse IL-4 gene. Retro virus producing cell lines were cultured, and medium was harvested for retro virus particles 24 hr later. Titers of MBT-2-IL-4 and MBT-2-GM-CSF were determined by ELISA kit. MBT-2-IL-2 cells were irradiated with 60 Gy gamma-ray and used to inoculate s.c. C3H mice. HER2/neu cDNA was cloned under the control of the SV40 virus promoter. Nucleic acid vaccine encoding tumor antigen neu was tested to improve the therapeutic efficacy. Coinjection of 60 ug plasmid pSV-neu DNA was effective in enhancing the antitumor effects of MTB2-IL, however, nucleic acid alone could not prevent the progression of the preexisting tumor. Immunohistochemical analysis of tumor infiltrate showed increased CD4+ lymphoid cell of mice treated

with nucleic acid vaccine and IL-2 secreted tumor vaccine. (59 ref)
 DESCRIPTORS: human interleukin-2, mouse interleukin-4 gene transfer, retro
 virus vector expression in mouse, pot. tumor cytokine-mediated gene

-more-

?

Display 6/9/8 (Item 3 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

therapy, nucleic acid vaccine mammal animal lymphokine protein gene
 transfer (Vol.20, No.3)

SECTION: PHARMACEUTICALS-Vaccines; PHARMACEUTICALS-Clinical Genetic
 Techniques; GENETIC ENGINEERING AND FERMENTATION-Nucleic Acid
 Technology (D4,D7,A1)

- end of record -

?

S VECTOR? (5N) EPITOPE? (5N) (CYTOKINE? OR IL-2 OR IL-4 OR INTERLEUKIN? OR GM-CSF) A
 Processing

Processed 10 of 37 files ...

Completed processing all files

2090978 VECTOR?

474263 EPITOPE?

1292311 CYTOKINE?

9162 IL-2

8235 IL-4

1318513 INTERLEUKIN?

14566 GM-CSF

131 VECTOR?(5N)EPITOPE?(5N)((((CYTOKINE? OR IL-2) OR IL-4) OR
 INTERLEUKIN?) OR GM-CSF)

345777 IMMUNOTHERAP?

4832279 CANCER

853836 VACCINE?

22783 CANCER(N)VACCINE?

S7 30 VECTOR? (5N) EPITOPE? (5N) (CYTOKINE? OR IL-2 OR IL-4 OR
 INTERLEUKIN? OR GM-CSF) AND (IMMUNOTHERAP? OR CANCER (N)
 VACCINE?)

?

RD S7

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.

...completed examining records

S8 17 RD S7 (unique items)

?

Display 8/3/1 (Item 1 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

17963959 PMID: 15868901

Stimulation of human T cells by an influenza A vector expressing a CTL
 epitope from the HER-2/neu protooncogene results in higher numbers of
 antigen-specific TCRhi cells than stimulation with peptide. Divergent roles
 of IL-2 and IL-15.

Efferson Clay L; Kawano Kouichiro; Tsuda Naotake; Palese Peter;
 Garcia-Sastre Adolfo; Ioannides Constantin G

Department of Gynecologic Oncology, M.D. Anderson Cancer Center, Houston,
Texas 77030, USA.

Anticancer research (Greece) Mar-Apr 2005, 25 (2A) p715-24, ISSN
0250-7005 Journal Code: 8102988

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

-more-

?

Display 8/3/1 (Item 1 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

Record type: MEDLINE; Completed

- end of record -

?

Display 8/3/2 (Item 2 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

14983717 PMID: 14505911

**Induction of murine ras oncogene peptide-specific T cell responses by
immunization with plasmid DNA-based minigene vectors.**

Lindinger Peter; Mostböck Sven; Hammerl Peter; Hartl Arnulf; Thalhamer
Josef; Abrams Scott I

Immunology Group, Institute of Chemistry and Biochemistry, University of
Salzburg, Salzburg, Austria.

Vaccine (Netherlands) Oct 1 2003, 21 (27-30) p4285-96, ISSN
0264-410X Journal Code: 8406899

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

- end of record -

?

Display 8/3/3 (Item 3 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

14650726 PMID: 12571632

**Priming of T cells with Ad-transduced DC followed by expansion with
peptide-pulsed DC significantly enhances the induction of tumor-specific
CD8+ T cells: implications for an efficient vaccination strategy.**

Tuettenberg A; Jonuleit H; Tuting T; Bruck J; Knop J; Enk A H

Department of Dermatology, J. Gutenberg-University, Langenbeckstrasse 1,
D-55101 Mainz, Germany.

Gene therapy (England) Feb 2003, 10 (3) p243-50, ISSN 0969-7128
Journal Code: 9421525

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

- end of record -

?

Display 8/3/4 (Item 4 from file: 154)

DIALOG(R) File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

14127030 PMID: 11907113

Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity.

Ali Selman A; Lynam June; McLean Cornelia S; Entwisle Claire; Loudon Peter; Rojas Jose M; McArdle Stephanie E B; Li Geng; Mian Shahid; Rees Robert C

Department of Life Sciences, Nottingham Trent University, Nottingham, United Kingdom.

Journal of immunology (Baltimore, Md. - 1950) (United States) Apr 1 2002, 168 (7) p3512-9, ISSN 0022-1767 Journal Code: 2985117R

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

-more-

?

Display 8/3/4 (Item 4 from file: 154)

DIALOG(R) File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

Main Citation Owner: NLM

Record type: MEDLINE; Completed

- end of record -

?

Display 8/3/5 (Item 5 from file: 154)

DIALOG(R) File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

14003706 PMID: 11751400

CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.

Ribas A; Butterfield L H; Amarnani S N; Dissette V B; Kim D; Meng W S; Miranda G A; Wang H J; McBride W H; Glaspy J A; Economou J S

Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, California 90095, USA.

Cancer research (United States) Dec 15 2001, 61 (24) p8787-93, ISSN 0008-5472 Journal Code: 2984705R

Contract/Grant No.: K12 CA76905; CA; NCI; R01 CA77623; CA; NCI; R01 CA79976; CA; NCI; T32 CA75956; CA; NCI

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

-more-

?

Display 8/3/5 (Item 5 from file: 154)

DIALOG(R) File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

Record type: MEDLINE; Completed

- end of record -

?

Display 8/3/6 (Item 6 from file: 154)

DIALOG(R) File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

13712570 PMID: 11359856

IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy.

Pertl U; Luster A D; Varki N M; Homann D; Gaedicke G; Reisfeld R A; Lode H N

Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Journal of immunology (Baltimore, Md. - 1950) (United States) Jun 1 2001, 166 (11) p6944-51, ISSN 0022-1767 Journal Code: 2985117R

Contract/Grant No.: CA69212; CA; NCI; CA83140; CA; NCI

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

-more-

?

Display 8/3/6 (Item 6 from file: 154)

DIALOG(R) File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

Record type: MEDLINE; Completed

- end of record -

?

Display 8/3/7 (Item 7 from file: 154)

DIALOG(R) File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

13697292 PMID: 11342612

Murine IL-10 gene transfer inhibits established collagen-induced arthritis and reduces adenovirus-mediated inflammatory responses in mouse liver.

Quattrocchi E; Dallman M J; Dhillon A P; Quaglia A; Bagnato G; Feldmann M
Kennedy Institute of Rheumatology Division, Imperial College School of Medicine, Hammersmith, London, United Kingdom.

Journal of immunology (Baltimore, Md. - 1950) (United States) May 15 2001, 166 (10) p5970-8, ISSN 0022-1767 Journal Code: 2985117R

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

- end of record -

?

Display 8/3/8 (Item 8 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

13618265 PMID: 11245465

Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.

Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafre S A; Vespignani I; Lazzari M; Farace M G; Saglio G; Fazio V M

Laboratory for Molecular and Biotechnology, Universita Campus Bio-Medico, Rome, Italy.

Cancer research (United States) Feb 15 2001, 61 (4) p1555-62, ISSN 0008-5472 Journal Code: 2984705R

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

-more-

?

Display 8/3/8 (Item 8 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

Record type: MEDLINE; Completed

- end of record -

?

Display 8/3/9 (Item 9 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

13259724 PMID: 9886439

High frequency of specific CD8+ T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer.

Fernandez N C; Levraud J P; Haddada H; Perricaudet M; Kourilsky P

Laboratoire de Vectorologie et Transfert de Genes, Centre National de la Recherche Scientifique-Unite Mixte de Recherche 1582, Institut Gustave Roussy, Villejuif, France.

Journal of immunology (Baltimore, Md. - 1950) (UNITED STATES) Jan 1 1999, 162 (1) p609-17, ISSN 0022-1767 Journal Code: 2985117R

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

- end of record -

?

Display 8/9/9 (Item 9 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

13259724 PMID: 9886439

High frequency of specific CD8+ T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer.

Fernandez N C; Levraud J P; Haddada H; Perricaudet M; Kourilsky P
Laboratoire de Vectorologie et Transfert de Genes, Centre National de la
Recherche Scientifique-Unité Mixte de Recherche 1582, Institut Gustave
Roussy, Villejuif, France.

Journal of immunology (Baltimore, Md. - 1950) (UNITED STATES) Jan 1
1999, 162 (1) p609-17, ISSN 0022-1767 Journal Code: 2985117R

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: AIM; INDEX MEDICUS; AIDS/HIV

-more-

?

Display 8/9/9 (Item 9 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

Cancer immunotherapy often aims at the reactivation and expansion of tumor-specific CTL. In an attempt to correlate in situ and/or systemic tumor-specific T cell expansion with tumor regression, we investigated the effects of adenovirus-mediated IL-12 or IFN-gamma gene transfer into established P815 murine tumors. While IFN-gamma was no more potent than the vector alone, IL-12 gene transfer promoted tumor eradication. Despite this antitumor effect, no significant cytolytic activity was detectable using classical cytotoxicity assays from in vitro restimulated splenocytes. Since intratumor gene delivery may induce a localized expansion of CTL, the presence of P815-specific CD8+ T cells in situ was assessed. Using the Immunoscope approach, we found a dramatic increase in clonotypic T cells at the tumor site following IL-12, but not IFN-gamma gene delivery. Antitumor CD8+ T cell frequencies were then re-evaluated using this molecular detection technique, which revealed a comparable expansion of specific T cells in the peripheral organs, most strikingly in the blood. These data show that local IL-12 gene transfer, in contrast to IFN-gamma, mediates a

-more-

?

Display 8/3/10 (Item 10 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

12903513 PMID: 10850282

Review: dendritic cell immunotherapy for melanoma.

Hadzantonis M; O'Neill H

Division of Biochemistry & Molecular Biology School of Life Sciences,
Australian National University, Canberra ACT, Australia.

Cancer biotherapy & radiopharmaceuticals (UNITED STATES) Feb 1999, 14
(1) p11-22, ISSN 1084-9785 Journal Code: 9605408

Publishing Model Print

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

- end of record -

?

Display 8/3/11 (Item 11 from file: 154)

DIALOG(R) File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

12683462 PMID: 10606260

Strategies in the development of recombinant vaccines for colon cancer.

Schlom J; Tsang K Y; Kantor J A; Abrams S I; Zaremba S; Greiner J; Hodge J W

Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1750, USA.

Seminars in oncology (UNITED STATES) Dec 1999, 26 (6) p672-82, ISSN 0093-7754 Journal Code: 0420432

Publishing Model Print

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

- end of record -

?

Display 8/9/11 (Item 11 from file: 154)

DIALOG(R) File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

12683462 PMID: 10606260

Strategies in the development of recombinant vaccines for colon cancer.

Schlom J; Tsang K Y; Kantor J A; Abrams S I; Zaremba S; Greiner J; Hodge J W

Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1750, USA.

Seminars in oncology (UNITED STATES) Dec 1999, 26 (6) p672-82, ISSN 0093-7754 Journal Code: 0420432

Publishing Model Print

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

A new era involving the evaluation of recombinant vaccines for colon

-more-

?

Display 8/9/11 (Item 11 from file: 154)

DIALOG(R) File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

cancer has begun with the concurrent emergence of insights and technologies in the fields of molecular biology and immunology. These advances include (1) the identification and cloning of an array of genes associated with the neoplastic process, such as oncogenes, suppressor genes, genes encoding oncofetal antigens, and tissue lineage determinants; (2) the development of a variety of viral and bacterial vectors to deliver and present gene products; (3) the identification of numerous T-cell costimulatory molecules and the knowledge of their mode of action; (4) the cloning and analysis of the modes of action of an array of cytokines and other immunomodulatory molecules; and (5) a more sophisticated knowledge of the mode(s) of antigen presentation and T-cell activation. (92 Refs.)

Descriptors: *Cancer Vaccines; *Colorectal Neoplasms --prevention and control--PC; Adjuvants, Immunologic; Animals; Antigen Presentation; Antigens, Neoplasm; Carcinoembryonic Antigen; Clinical Trials; Colorectal

Neoplasms--genetics--GE; Colorectal Neoplasms--immunology--IM; Cytokines;
Drug Evaluation, Preclinical; Epitopes; Gene Expression Regulation,

-more-

?

Display 8/9/11 (Item 11 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

Neoplastic; Genes, ras; Genetic Vectors; Humans; Lymphocyte Activation;
Point Mutation; T-Lymphocytes

CAS Registry No.: 0 (Adjuvants, Immunologic); 0 (Antigens, Neoplasm);
0 (Cancer Vaccines); 0 (Carcinoembryonic Antigen); 0 (Cytokines); 0
(Epitopes); 0 (Genetic Vectors)

Record Date Created: 19991223

Record Date Completed: 19991223

- end of record -

?

Display 8/3/12 (Item 12 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

11589609 PMID: 8900434

**Growth retardation of tumors by adoptive transfer of cytotoxic T
lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera.**

Hekele A; Dall P; Moritz D; Wels W; Groner B; Herrlich P; Ponta H

Research Center Karlsruhe, Institute of Genetics, Germany.

International journal of cancer. Journal international du cancer (UNITED
STATES) Oct 9 1996, 68 (2) p232-8, ISSN 0020-7136 Journal Code:
0042124

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

- end of record -

?

Display 8/3/13 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

142275032 CA: 142(15)275032h PATENT

**Poxvirus vector encoding prostate specific antigens and cytokines for
treatment of prostate cancer**

INVENTOR(AUTHOR): Brown, Michael Paul; Howley, Paul Michael

LOCATION: Australia

ASSIGNEE: Virax Development Pty. Ltd.

PATENT: PCT International ; WO 200519464 A1 DATE: 20050303

APPLICATION: WO 2004AU1129 (20040820) *AU 20032003904496 (20030821)

PAGES: 86 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/863A;
A61K-039/00B; A61P-035/00B; C12N-015/12B DESIGNATED COUNTRIES: AE; AG; AL;
AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE;
DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS;
JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW;
MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL;
SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW

-more-

?

Display 8/3/13 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK;
EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR;
BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

- end of record -

?

Display 8/3/14 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

141105249 CA: 141(7)105249w PATENT

**Recombinant viral vectors expressing IL-15 and antigen epitope for
vaccines against viral or bacterial infection and cancer**

INVENTOR(AUTHOR): Perera, Liyange P.; Waldmann, Thomas A.; Oh, Sang-kon;
Berzofsky, Jay A.

LOCATION: USA

ASSIGNEE: The Government of the United States of America, as Represented
by the Secretary Department of Health and Human Services

PATENT: PCT International ; WO 200458278 A1 DATE: 20040715

APPLICATION: WO 2003US39967 (20031215) *US PV433703 (20021216)

PAGES: 81 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-035/00A;
A61K-048/00B; C12N-015/63B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU;
AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC;
EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR;
KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ;

-more-

?

Display 8/3/14 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT;
TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM;
; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU;
TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT;
LU; MC; NL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR; NE; SN; TD; TG

- end of record -

?

Display 8/3/15 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

138400416 CA: 138(26)400416g PATENT

**Immunogenic variants of recombinant polymeric autologous proteins for
active immunotherapy**

INVENTOR(AUTHOR): Klysner, Steen; Nielsen, Finn Stausholm; Bratt, Tomas;
Voldborg, Bjorn; Mouritsen, Soren

LOCATION: Den.

ASSIGNEE: Pharmexa A/S

PATENT: PCT International ; WO 200342244 A2 DATE: 20030522

APPLICATION: WO 2002DK764 (20021115) *DK 20011702 (20011116) *US PV331575 (20011116)

PAGES: 196 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-014/54A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH;

-more-

?

Display 8/3/15 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

PL; PT; RO; RU; SC; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

- end of record -

?

Display 8/3/16 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0254060 DBR Accession No.: 2000-08550

Augmentation of antitumor immunity by genetically engineered fibroblast cells to express both B7.1 and interleukin-7 - fibroblast genetically modified to express B7.1, interleukin-7 and ovalbumin, used to induce an antitumor immune response

AUTHOR: Kim T S; Chung S W; Hwang S Y

CORPORATE AFFILIATE: Univ.Chonnam-Nat. Univ.Hanyang

CORPORATE SOURCE: College of Pharmacy and Research Institute of Drug

Development, Chonnam National University, Kwangju 500-757, South Korea.

email:taekim@chonnam.chonnam.ac.kr

JOURNAL: Vaccine (18, 25, 2886-94) 2000

ISSN: 0264-410X CODEN: VACCDE

LANGUAGE: English

- end of record -

?

Display 8/9/16 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0254060 DBR Accession No.: 2000-08550

Augmentation of antitumor immunity by genetically engineered fibroblast cells to express both B7.1 and interleukin-7 - fibroblast genetically modified to express B7.1, interleukin-7 and ovalbumin, used to induce an antitumor immune response

AUTHOR: Kim T S; Chung S W; Hwang S Y

CORPORATE AFFILIATE: Univ.Chonnam-Nat. Univ.Hanyang

CORPORATE SOURCE: College of Pharmacy and Research Institute of Drug

Development, Chonnam National University, Kwangju 500-757, South Korea.

email:taekim@chonnam.chonnam.ac.kr

JOURNAL: Vaccine (18, 25, 2886-94) 2000

ISSN: 0264-410X CODEN: VACCDE

LANGUAGE: English

ABSTRACT: Mouse fibroblasts genetically engineered using plasmid pZipNeoSV to express a costimulatory B7.1 protein, and interleukin-7 (IL-7) were

-more-

?

Display 8/9/16 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

subsequently pulsed with an ovalbumin (OVA) epitope, and tested for the ability to induce OVA-specific cytotoxic T-lymphocytes in C57BL/6 mice. Fibroblasts that lacked either B7.1 or IL-7 were used as controls. Immunization with the fibroblasts (I) encoding B7.1, IL-7 and OVA induced strong cytotoxic activity against OVA-expressing EL4 tumor cells. The cytotoxic immune response in mice treated with (I) was significantly higher than in mice treated with other cell constructs. CD8+ T-lymphocytes were a major effector cell-type for the antitumor response in mice treated with the (I) fibroblasts. Immunization with the (I) cells also extended the survival period of mice injected with EG7 tumor cells a week after immunization. The results indicate fibroblasts can be genetically modified to produce an efficient cellular vaccine that can be used to produce an anti-tumor immune response. (37 ref)

DESCRIPTORS: recombinant B7.1 protein, interleukin-7, ovalbumin epitope vector plasmid pZipNeoSV-B7.1, plasmid pZipNeoSV-IL-7-mediated gene

-more-

?

Display 8/3/17 (Item 1 from file: 35)

DIALOG(R)File 35:Dissertation Abs Online

(c) 2005 ProQuest Info&Learning. All rts. reserv.

01978197 ORDER NO: AADAA-I3108907

Incorporation of tumor antigen epitopes into cytokine signal peptides enhance the efficacy of immuno-gene therapy

Author: He, Xianghui

Degree: Ph.D.

Year: 2003

Corporate Source/Institution: The University of Arizona (0009)

Source: VOLUME 64/10-B OF DISSERTATION ABSTRACTS INTERNATIONAL.
PAGE 4850. 170 PAGES

- end of record -

?

?

?